Clinical Trial Update: BAY59-7939 in Atrial Fibrillation Once Daily (OD) [Phase 2]

View source ↗

Summary

Phase 2 trial of BAY59-7939 for atrial fibrillation has completed; no efficacy or safety results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• BAY59-7939

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED